DCR-M1711

N/A

Report date: 2022/07/19 16:22:54
NME

Base Information

Drug NameDCR-M1711
Drug Alias Nameanti-Myc DsiRNAsDCR-MYCDCR-M1711
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionMyc proto-oncogene protein inhibitorsRNA interference
TargetsMyc proto-oncogene protein
Therapy Area/IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursMultiple Myeloma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesSingaporeSouth Korea
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesDicerna Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesDicerna Pharmaceuticals Inc
Active IndicationsN/A
Inactive IndicationsPancreatic neuroendocrine tumors (pNET)Solid tumoursMultiple Myeloma +[6] 

Other Information

ATC CodeN/A
Related LinksN/A